CagriSema: Novo Nordisk's Dual-Action Weight Loss Combo Coming to South Africa (2026 Guide)

You already know about Ozempic and Wegovy. You have probably read about Mounjaro and retatrutide. But Novo Nordisk -- the same company behind semaglutide -- has a new combination drug that could leapfrog them all: CagriSema.

CagriSema pairs cagrilintide (a long-acting amylin analog) with semaglutide (the GLP-1 agonist in Ozempic) into a single weekly injection. In Phase 3 trials, it delivered 22.7% average body weight loss -- roughly 7 percentage points more than semaglutide alone. For South Africans struggling with obesity and looking beyond what current medications offer, CagriSema represents the next frontier.

What Is CagriSema?

CagriSema is a fixed-dose combination of two drugs in one pen:

• Cagrilintide -- a long-acting analog of amylin, a hormone naturally produced by the pancreas alongside insulin. Amylin slows gastric emptying, reduces glucagon secretion, and promotes satiety through the brainstem. Natural amylin is cleared in minutes; cagrilintide lasts a full week.
• Semaglutide 2.4 mg -- the same GLP-1 receptor agonist used in Wegovy, which suppresses appetite via hypothalamic signalling, slows stomach emptying, and improves insulin sensitivity.

The logic is straightforward: GLP-1 and amylin regulate appetite through different brain pathways. Targeting both simultaneously produces greater appetite suppression and weight loss than either mechanism alone. Think of it like combining two different locks on the same door -- the body's hunger signals have a much harder time getting through.

REDEFINE Trial Results: The Numbers

Novo Nordisk tested CagriSema in a large Phase 3 programme called REDEFINE. The headline trial, REDEFINE 1, enrolled 3,417 adults with obesity (BMI 30 or above, or BMI 27+ with at least one weight-related comorbidity) across multiple countries.

REDEFINE 1 -- Weight Loss at 68 Weeks

Source: Novo Nordisk REDEFINE 1 Phase 3 topline results (presented at ObesityWeek 2024). Full peer-reviewed publication pending.

The key takeaway: CagriSema delivered nearly 7 additional percentage points of weight loss compared to the same dose of semaglutide alone. That is clinically meaningful -- it is the difference between losing 16 kg and losing 23 kg for someone starting at 100 kg.

REDEFINE 2 -- Type 2 Diabetes Population

CagriSema was also tested in people with obesity and type 2 diabetes (REDEFINE 2). Patients with diabetes typically lose less weight on GLP-1 drugs. Results:

• CagriSema: 15.7% body weight loss at 68 weeks
• Semaglutide 2.4 mg alone: 12.1%
• HbA1c reduction with CagriSema: approximately 1.8 percentage points (strong glycaemic control)

Even in the harder-to-treat diabetes population, CagriSema outperformed semaglutide alone -- and delivered blood sugar improvements that could reduce or eliminate the need for other diabetes medications.

How CagriSema Compares to Other Weight Loss Drugs

Pricing estimates based on international launch prices, exchange rates, and local pharmaceutical markup patterns. Actual SA prices will depend on SAHPRA approval and Novo Nordisk's pricing strategy.

Why the Amylin Pathway Matters

Most of the weight loss drugs making headlines right now -- Ozempic, Mounjaro, retatrutide -- work primarily through GLP-1 and related gut hormone pathways. CagriSema takes a different approach by adding amylin into the equation.

Amylin is a pancreatic hormone that:

• Signals fullness via the brainstem (area postrema), a different neural pathway than GLP-1's hypothalamic signalling
• Slows gastric emptying through a complementary mechanism to GLP-1
• Suppresses glucagon, reducing the liver's glucose output after meals
• Reduces food reward -- emerging research suggests amylin dampens the pleasure-driven motivation to eat, not just hunger

By engaging the brainstem pathway (amylin) alongside the hypothalamic pathway (GLP-1), CagriSema creates a more comprehensive appetite suppression system. This is why patients in trials lost significantly more weight than those on semaglutide alone -- even though they were already getting the full Wegovy dose.

Side Effects and Safety Profile

The side effect profile of CagriSema is largely consistent with what is seen with semaglutide side effects:

• Nausea: reported in approximately 40-45% of CagriSema participants (vs ~40% for semaglutide alone)
• Diarrhoea: ~20%
• Vomiting: ~15%
• Constipation: ~12%

Most GI side effects occurred during the dose-escalation phase and improved once patients reached their maintenance dose. Serious adverse events were uncommon and occurred at similar rates across all treatment groups, including placebo.

When Will CagriSema Be Available in South Africa?

Here is the realistic timeline:

1. US FDA submission: Novo Nordisk submitted a Biologics License Application (BLA) for CagriSema in late 2024. The FDA decision (PDUFA date) is expected in late 2025 or early 2026.
2. EMA / international approvals: European and other major market submissions are expected to follow the US filing.
3. SAHPRA registration: Novo Nordisk would need to submit a separate application to SAHPRA. Based on precedent (Wegovy's SA path), this could take 12-24 months after the first major international approval.
4. SA pharmacy availability: Earliest realistic estimate is late 2027 or 2028.

Novo Nordisk already has strong distribution infrastructure in South Africa through its existing Ozempic and Wegovy supply chains via Dis-Chem, Clicks, and independent pharmacies. This could speed up the local launch once SAHPRA approval is granted.

Cost and Medical Aid Coverage in South Africa

Pricing has not been announced for any market, but here is what we can reasonably estimate for South Africa:

• CagriSema estimated cost: R4,500 - R8,000 per month
• This reflects a premium over Wegovy (semaglutide 2.4 mg, currently R3,000-R5,000/mo at SA pharmacies) due to the added cagrilintide component
• Medical aid: Coverage will depend on scheme rules, but the strong clinical data could help. Patients with obesity plus comorbidities (type 2 diabetes, cardiovascular disease, sleep apnoea) are most likely to qualify for medical aid reimbursement

CagriSema vs Semaglutide: Is the Combo Worth It?

If you are already getting good results on Wegovy or Ozempic, you might wonder whether switching to CagriSema would be worthwhile. Consider these factors:

• Plateau breakers: Some patients hit a weight loss plateau on semaglutide after 6-12 months. CagriSema's dual mechanism could push through that plateau by engaging the amylin pathway
• Higher starting BMI: Patients with BMI above 40 may benefit more from the additional 7 percentage points of weight loss -- at 130 kg, that is the difference between losing 21 kg and losing 30 kg
• Diabetes management: If you have type 2 diabetes and are not reaching target HbA1c on semaglutide alone, CagriSema's stronger glycaemic effect could reduce your need for other diabetes medications
• Cost consideration: If Wegovy is working well and you have reached a healthy weight, the additional cost of CagriSema may not be justified. Talk to your doctor about your specific goals

What to Do Right Now

CagriSema is not available in South Africa yet, but here is how to prepare:

1. Start with what is available: If your doctor recommends a GLP-1 medication, Ozempic and Wegovy are available at Dis-Chem and Clicks pharmacies across South Africa right now
2. Build your medical file: Document everything -- BMI measurements, blood work, comorbidity diagnoses, previous diet attempts. This file will be essential when applying for medical aid coverage of newer drugs
3. Focus on lifestyle foundations: Medications work best when combined with a solid high-protein diet, regular exercise, and sustainable habits. Consider intermittent fasting as a complementary approach
4. Watch for SAHPRA updates: We will update this page as new information becomes available about CagriSema's South African registration timeline
5. Consult your doctor: A GP with interest in obesity medicine, an endocrinologist, or a bariatric physician can advise on the best current options and prepare you for newer treatments when they arrive

The Bottom Line

CagriSema represents a genuine step forward in obesity pharmacotherapy. By combining two distinct appetite-suppression pathways -- amylin and GLP-1 -- in a single weekly injection, it delivers weight loss results that exceed what semaglutide can achieve alone. The 22.7% average weight loss in Phase 3 trials places it among the most effective non-surgical weight loss interventions ever tested.

For South Africans, the wait continues. But with Novo Nordisk's established SA infrastructure and the growing recognition of obesity as a chronic disease requiring medical treatment, CagriSema is likely to reach our pharmacies within the next two years. In the meantime, current options like Ozempic, Wegovy, and lifestyle interventions including low-carb diets, Mediterranean diets, and calorie deficit strategies remain effective tools for weight management.

Speak to your healthcare provider about what is right for you -- and check back here for updates as CagriSema moves closer to SA approval.

Last updated: June 2026. This article will be updated as new clinical data and regulatory decisions are announced.